| 4LL Stock | | | EUR 9.02 0.34 3.92% |
Director
Mr. David L. Shedlarz is an Independent Director of the TELADOC, INC. He is the former vice chairman, executive vice president and chief financial officer of Pfizer, Inc., having had worldwide responsibility for the companys former Medical Technology Group. During his 31year tenure at Pfizer, Mr. Shedlarz played a key role in shaping the strategic direction that drove the companys impressive growth and helped establish it as an industry leader and innovator. Among his senior leadership roles were that of executive vice president beginning in 1999, and then vice chairman in 2005, serving until his retirement in 2007 since 2016.
| Age | 70 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 203 635 2002 |
| Web | https://www.teladochealth.com |
Shedlarz sits on the boards of The Hershey Company, Pitney Bowes Inc. and the Teacher Insurance and Annuity Association. He holds a MBA in finance and accounting from New York University, Leonard N. Stern School of Business, and a BS in economics and mathematics from Oakland/Michigan State University. Our Board has concluded that Mr. Shedlarz should serve as a director because of his deep experience in public company finance, his experience as a director of large public companies and his prior service as the chief financial officer of one of the world’s leading pharmaceutical corporations.
Teladoc Management Efficiency
The company has return on total asset
(ROA) of
(0.0129) % which means that it has lost $0.0129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.4885) %, meaning that it generated substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities.
Teladoc has accumulated 1.54
B in total debt with debt to equity ratio
(D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Teladoc has a current ratio of 3.88, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Teladoc until it has trouble settling it off, either with new capital or with free cash flow. So, Teladoc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teladoc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teladoc to invest in growth at high rates of return. When we think about Teladoc's use of debt, we should always consider it together with cash and equity.
Similar Executives
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York. TELADOC HEALTH operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 3652 people. Teladoc (4LL) is traded on Frankfurt Exchange in Germany and employs 37 people.
Management Performance
Teladoc Leadership Team
Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Goldstein, Independent Director | |
| Mike Waters, Chief Officer | |
| Andrew Turitz, Senior Vice President of Business Development | |
| Catherine Jacobson, Independent Director | |
| Sandra Fenwick, Director | |
| Michelle Bucaria, Chief Human Resource Officer | |
| Christopher Bischoff, Director | |
| David Shedlarz, Independent Director | |
| William Frist, Independent Director | |
| Mala Murthy, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller | |
| Mark Smith, Independent Director | |
| David Snow, Independent Chairman of the Board | |
| David Sides, Chief Operating Officer | |
| Richard Napolitano, Chief VP | |
| Thomas McKinley, Independent Director | |
| Christopher Caridi, Senior Vice President Chief Accounting Officer, Controller | |
| Karen Daniel, Director | |
| Lewis Levy, Chief Medical Officer | |
| Claus Jensen, Chief Officer | |
| Adam Vandervoort, Chief Legal Officer and Secretary | |
| Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller | |
| Kenneth Paulus, Independent Director | |
| Stephanie Verstraete, Chief Marketing Officer | |
| George Brooks, CoFounder | |
| Hemant Taneja, Director | |
| Glen Tullman, Director | |
| Helen Darling, Independent Director | |
| CPA CFA, VP Relations | |
| Jason Gorevic, Chief Executive Officer, Director | |
| Courtney McLeod, Director Communication | |
Teladoc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Teladoc Stock
When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Teladoc Stock please use our
How to Invest in Teladoc guide.
You can also try the
Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.